Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension.

Next Previous
Trial Profile

A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren (Primary) ; Losartan
  • Indications Essential hypertension; Hypertension; Left ventricular hypertrophy
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms ALLAY; ASPIRE-HIGHER
  • Sponsors Novartis

    • Most Recent Events

    • 09 May 2011 Additional trial locations (Argentina, Colombia, Finland, Italy, Russia, Spain, Sweden) added as reported by ClinicalTrials.gov
    • 15 Jun 2009 Pharmcodynamic results presented at the 19th European Meeting on Hypertension, 2009.
    • 03 Feb 2009 Resulted reported in Circulation, 3 February 2009.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top